Acetylation in Tumor Immune Evasion Regulation

Jun Lu; Xiang He; Lijuan Zhang; Ran Zhang; Wenzheng Li

doi:10.3389/fphar.2021.771588

Acetylation in Tumor Immune Evasion Regulation

Front Pharmacol. 2021 Nov 22:12:771588. doi: 10.3389/fphar.2021.771588. eCollection 2021.

Authors

Jun Lu^{1

2}, Xiang He^{2

3}, Lijuan Zhang⁴, Ran Zhang¹, Wenzheng Li⁴

Affiliations

¹ Hunan Normal University School of Medicine, Changsha, China.
² Key Laboratory of Molecular Radiation Oncology Hunan Province, Changsha, China.
³ Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha, China.
⁴ Department of Radiology, Xiangya Hospital, Central South University, Changsha, China.

Abstract

Acetylation is considered as one of the most common types of epigenetic modifications, and aberrant histone acetylation modifications are associated with the pathological process of cancer through the regulation of oncogenes and tumor suppressors. Recent studies have shown that immune system function and tumor immunity can also be affected by acetylation modifications. A comprehensive understanding of the role of acetylation function in cancer is essential, which may help to develop new therapies to improve the prognosis of cancer patients. In this review, we mainly discussed the functions of acetylase and deacetylase in tumor, immune system and tumor immunity, and listed the information of drugs targeting these enzymes in tumor immunotherapy.

Keywords: acetylases; acetylated modifications; cancer immunotherapy; deacetylases; tumor immunity.

Publication types

Review